Triphase Accelerator Corp. entered into a strategic relationship with Celgene Corporation. Through this arrangement, Celgene obtained rights of first refusal on the first three oncology products Triphase advances to clinical proof-of-concept (POC), plus a right of first negotiation on three more future oncology products which may be acquired by Triphase.

Triphase is actively seeking additional products for licensing and development, consistent with its mission to accelerate products to Phase II development.